Issue 23, 2024

Dual delivery of carbon monoxide and doxorubicin using haemoglobin–albumin cluster: proof of concept for well-tolerated cancer therapy

Abstract

A serious concern of doxorubicin (DOX) therapy is that it causes severe adverse effects, particularly cardiotoxicity. Carbon monoxide (CO) possesses powerful cytoprotective effects against drug-induced organ injury and is expected to ameliorate DOX-induced cardiotoxicity. In this study, a dual carrier of DOX and CO (CO-HemoAct-DOX) was fabricated based on a haemoglobin–albumin cluster (HemoAct), which is a protein cluster with a haemoglobin core structure wrapped by serum albumin. CO-HemoAct-DOX was synthesised by binding CO to a haemoglobin core and covalently conjugating (6-maleimidocaproyl)hydrazone derivative of DOX to an albumin shell. The average DOX/cluster ratio was about 2.6. In the in vitro cytotoxicity assay against cancer cells, the anti-tumour activity of CO-HemoAct-DOX was 10-fold lower than that of DOX in a 2D-cultured model, whereas CO-HemoAct-DOX suppressed the growth of tumour spheroids to the same extent as DOX in the 3D-cultured model. In colon-26 tumour-bearing mice, CO-HemoAct-DOX achieved DOX delivery to the tumour site and alleviated tumour growth more effectively than DOX. Furthermore, CO-HemoAct attenuated DOX-induced cardiomyocyte atrophy in H9c2 cells and elevated the levels of cardiac biomarkers in mice exposed to DOX. These results suggest that the dual delivery of CO and DOX using HemoAct is a promising strategy as an anti-tumour agent to realise well-tolerated cancer therapy with minimal cardiotoxicity.

Graphical abstract: Dual delivery of carbon monoxide and doxorubicin using haemoglobin–albumin cluster: proof of concept for well-tolerated cancer therapy

Supplementary files

Article information

Article type
Paper
Submitted
18 Jan 2024
Accepted
04 May 2024
First published
07 May 2024

J. Mater. Chem. B, 2024,12, 5600-5608

Dual delivery of carbon monoxide and doxorubicin using haemoglobin–albumin cluster: proof of concept for well-tolerated cancer therapy

C. Ito, K. Taguchi, T. Yamada, K. Hanaya, Y. Enoki, T. Sugai, T. Komatsu and K. Matsumoto, J. Mater. Chem. B, 2024, 12, 5600 DOI: 10.1039/D4TB00123K

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements